TORNTPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | TORNTPHARM | Market Cap | 1,42,431 Cr. | Current Price | 4,211 ₹ | High / Low | 4,483 ₹ |
| Stock P/E | 63.8 | Book Value | 250 ₹ | Dividend Yield | 0.76 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,170 ₹ | DMA 200 | 3,786 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.12 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 45.0 | MACD | 43.2 | Volume | 2,08,242 | Avg Vol 1Wk | 3,79,968 |
| Low price | 3,101 ₹ | High price | 4,483 ₹ | PEG Ratio | 2.62 | Debt to equity | 0.25 |
| 52w Index | 80.3 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 27.2 |
📊 TORNTPHARM demonstrates strong fundamentals with excellent ROE (26.2%) and ROCE (27.8%), reflecting efficient capital use. The company has consistent profitability with EPS of 65 ₹ and a healthy quarterly PAT (584 Cr.). Debt-to-equity is low at 0.25, ensuring financial stability. However, the stock trades at a high P/E (63.8) compared to the industry average (27.2), and the PEG ratio (2.62) indicates valuations are stretched relative to growth. Dividend yield is modest (0.76%). Technical indicators (RSI 45, MACD 43.2) show neutral-to-positive momentum, with the stock trading near its 50 DMA (4,170 ₹) and above its 200 DMA (3,786 ₹).
💰 Ideal Entry Price Zone: Investors can consider accumulating between 4,000–4,150 ₹, close to DMA support levels. A deeper value entry would be near 3,700–3,800 ₹ if market weakness provides an opportunity.
📈 Exit Strategy / Holding Period: For existing holders, TORNTPHARM is a strong candidate for long-term holding (5+ years) given its efficiency metrics and sectoral demand. Partial profit booking can be considered near 4,400–4,450 ₹ if valuations remain stretched. Otherwise, continue holding for compounding returns, as the company remains financially stable and well-positioned in the pharmaceutical sector.
✅ Positive
- Strong ROE (26.2%) and ROCE (27.8%).
- Low debt-to-equity ratio (0.25), ensuring financial stability.
- EPS of 65 ₹ indicates consistent profitability.
- Technical indicators show neutral-to-positive momentum (MACD positive).
⚠️ Limitation
- High P/E (63.8) compared to industry PE (27.2), suggesting overvaluation.
- PEG ratio (2.62) indicates valuations stretched relative to growth.
- Dividend yield modest at 0.76%.
- Quarterly PAT declined slightly (584 Cr. vs 606 Cr.).
📉 Company Negative News
- Sequential decline in quarterly profits.
- High valuation multiples compared to peers.
📈 Company Positive News
- Strong EPS and profitability despite slight PAT decline.
- FII holdings increased (+0.21%), showing foreign investor confidence.
- Stock trading near support levels, offering accumulation opportunities.
🏭 Industry
- Industry PE is 27.2, much lower than TORNTPHARM’s valuation, highlighting premium pricing.
- Pharmaceutical sector benefits from steady demand and global healthcare expansion.
🔎 Conclusion
TORNTPHARM is a fundamentally strong company with efficient capital use, low debt, and consistent profitability. While valuations are stretched compared to industry peers, its growth trajectory and sectoral demand make it a good candidate for long-term investment. Ideal entry is near 4,000–4,150 ₹, with a holding horizon of 5+ years. Existing investors should continue holding, with partial profit booking near 4,400–4,450 ₹ if valuations remain high.